IndexIQ Advisors’s Myriad Genetics MYGN Stock Holding History

IndexIQ Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$398K	Buy	15,792 +1,923	+14%	+$49.2K	0.01%	732
2021 Q4	$383K	Sell	13,869 -896	-6%	-$26K	0.01%	813
2021 Q3	$477K	Buy	14,765 +1,479	+11%	+$49.1K	0.02%	596
2021 Q2	$406K	Sell	13,286 -478	-3%	-$13.8K	0.01%	687
2021 Q1	$419K	Sell	13,764 -872	-6%	-$24.7K	0.01%	457
2020 Q4	$289K	Buy	14,636 +1,511	+12%	+$24.4K	0.01%	701
2020 Q3	$171K	Buy	13,125 +712	+6%	+$9.01K	0.01%	771
2020 Q2	$141K	Sell	12,413 -480	-4%	-$6.82K	0.01%	804
2020 Q1	$184K	Buy	+12,893	New	+$272K	0.01%	595

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

IndexIQ Advisors's MYGN Position: Q1 2022 in Review

IndexIQ Advisors increased its Myriad Genetics (MYGN) stake by 14% in Q1 2022, buying an estimated $49.2K and bringing the position to 15,792 shares worth $398K. The position accounts for 0.01% of the portfolio, ranked #732.

IndexIQ Advisors first reported a position in MYGN in Q1 2020 and has held it in 9 quarters since. The position peaked at $477K in Q3 2021. 205 funds tracked by Wall St. Rank hold MYGN as of Q1 2022.

IndexIQ Advisors held 15,792 shares of Myriad Genetics worth $398K as of Q1 2022.
IndexIQ Advisors bought 1,923 Myriad Genetics shares in Q1 2022, an estimated $49.2K.
Myriad Genetics made up 0.01% of IndexIQ Advisors's portfolio in Q1 2022, its #732 holding.
IndexIQ Advisors first reported a position in Myriad Genetics in Q1 2020 and has held it in 9 quarters since.
IndexIQ Advisors's Myriad Genetics position peaked at $477K in Q3 2021.
205 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2022.

Based on IndexIQ Advisors's 13F filing for Q1 2022, filed 6 May 2022.